US Patent

US9006387 — Anti-viral compounds

Method of Use · Assigned to AbbVie Inc · Expires 2030-06-10 · 4y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent describes compounds and processes for making them that inhibit the replication of the Hepatitis C virus.

USPTO Abstract

Compounds effective in inhibiting replication of Hepatitis C virus (âHCVâ) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1687`	—
`U-1687`	—
`U-1687`	—

Patent Metadata

Patent number: US9006387
Jurisdiction: US
Classification: Method of Use
Expires: 2030-06-10
Drug substance claim: No
Drug product claim: No
Assignee: AbbVie Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.